Αμισουλπρίδη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Αμισουλπρίδη" in Greek language version.

refsWebsite

Global rank Greek rank

23nih.gov

4^th place

21doi.org

2^nd place

3^rd place

7archive.org

6^th place

5^th place

4lbpharma.us

low place

2tga.gov.au

3,984^th place

2,133^rd place

2web.archive.org

1^st place

2worldcat.org

5^th place

8^th place

2books.google.com

3^rd place

6^th place

1drugs.com

399^th place

130^th place

1medicines.org.uk

3,823^rd place

2,141^st place

1fda.gov

447^th place

368^th place

1medicinescomplete.com

low place

5,144^th place

archive.org

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G. (2002). «A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers». Human Psychopharmacology 17 (1): 1–13. doi:10.1002/hup.320. PMID 12404702. https://archive.org/details/sim_human-psychopharmacology_2002-01_17_1/page/n6.
Joint Formulary Committee (2013). British National Formulary (BNF) (65 έκδοση). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
Joint Formulary Committee, BMJ, επιμ. (Μαρτίου 2009). «4.2.1». British National Formulary (57 έκδοση). United Kingdom: Royal Pharmaceutical Society of Great Britain. σελ. 192. ISBN 978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
Isbister, GK; Balit, CR; Macleod, D; Duffull, SB (August 2010). «Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes». Journal of Clinical Psychopharmacology 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID 20531221. https://archive.org/details/sim_journal-of-clinical-psychopharmacology_2010-08_30_4/page/391.
Joy, JP; Coulter, CV; Duffull, SB; Isbister, GK (August 2011). «Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses». Clinical Pharmacology & Therapeutics 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID 21716272. https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2011-08_90_2/page/243.
Taylor, D· Paton, C (2012). Maudsley Prescribing Guidelines in Psychiatry (11th έκδοση). West Sussex: Wiley-Blackwell. ISBN 978-0-47-097948-8.
«Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo». Psychopharmacology 205 (1): 119–28. 2009. doi:10.1007/s00213-009-1521-8. PMID 19337725. PMC 2821721. https://archive.org/details/sim_psychopharmacology_2009-07_205_1/page/119.

books.google.com

Haddad, Peter· Haddad, Peter M. (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide (στα Αγγλικά). OUP Oxford. σελίδες 207–216. ISBN 9780198527480.
Sacchetti, Emilio· Vita, Antonio (2013). Adherence to Antipsychotics in Schizophrenia (στα Αγγλικά). Springer Science & Business Media. σελ. 85. ISBN 9788847026797.

doi.org

dx.doi.org

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G. (2002). «A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers». Human Psychopharmacology 17 (1): 1–13. doi:10.1002/hup.320. PMID 12404702. https://archive.org/details/sim_human-psychopharmacology_2002-01_17_1/page/n6.
Caccia, S (May 2000). «Biotransformation of Post-Clozapine Antipsychotics Pharmacological Implications». Clinical Pharmacokinetics 38 (5): 393–414. doi:10.2165/00003088-200038050-00002. PMID 10843459.
Noble, S; Benfield, P (December 1999). «Amisulpride: A Review of its Clinical Potential in Dysthymia». CNS Drugs 12 (6): 471–483. doi:10.2165/00023210-199912060-00005.
«The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia». Molecular Psychiatry 7 (3): 247–53. 2002. doi:10.1038/sj.mp.4001040. PMID 11920152.
Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C και άλλοι. (September 2013). «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
De Silva, V; Hanwella, R (April 2008). «Pharmaceutical patents and the quality of mental healthcare in low- and middle-income countries». The Psychiatrist 32 (4): 121–23. doi:10.1192/pb.bp.107.015651.
«Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7». ACS Omega 4 (9): 14151–4. August 2019. doi:10.1021/acsomega.9b02144. ISSN 2470-1343. PMID 31497735.
Komossa, K; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI; Kissling, W; Leucht, S (January 2010). «Amisulpride versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (1): CD006624. doi:10.1002/14651858.CD006624.pub2. PMID 20091599.
Leucht, S; Corves, C; Arbter, D; Engel, RR; Li, C; Davis, JM (January 2009). «Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis». Lancet 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842.
Solanki, RK; Sing, P; Munshi, D (Oct–Dec 2009). «Current perspectives in the treatment of resistant schizophrenia». Indian Journal of Psychiatry 51 (4): 254–60. doi:10.4103/0019-5545.58289. PMID 20048449.
Mouaffak, F; Tranulis, C; Gourevitch, R; Poirier, MF; Douki, S; Olié, JP; Lôo, H; Gourion, D (2006). «Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia». Clinical Neuropharmacology 29 (1): 28–33. doi:10.1097/00002826-200601000-00009. PMID 16518132.
Nuss, P.; Hummer, M.; Tessier, C. (2007). «The use of amisulpride in the treatment of acute psychosis». Therapeutics and Clinical Risk Management 3 (1): 3–11. doi:10.2147/tcrm.2007.3.1.3. PMID 18360610.
McKeage, K; Plosker, GL (2004). «Amisulpride: a review of its use in the management of schizophrenia». CNS Drugs 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. ISSN 1172-7047. PMID 15521794.
Natesan, S; Reckless, GE; Barlow, KB; Nobrega, JN; Kapur, S (October 2008). «Amisulpride the 'atypical' atypical antipsychotic — Comparison to haloperidol, risperidone and clozapine». Schizophrenia Research 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID 18710798.
«Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica 114 (1): 3–13. July 2006. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
Isbister, GK; Balit, CR; Macleod, D; Duffull, SB (August 2010). «Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes». Journal of Clinical Psychopharmacology 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID 20531221. https://archive.org/details/sim_journal-of-clinical-psychopharmacology_2010-08_30_4/page/391.
Joy, JP; Coulter, CV; Duffull, SB; Isbister, GK (August 2011). «Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses». Clinical Pharmacology & Therapeutics 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID 21716272. https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2011-08_90_2/page/243.
Levine, M; Ruha, AM (July 2012). «Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management». CNS Drugs 26 (7): 601–611. doi:10.2165/11631640-000000000-00000. PMID 22668123.
«Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo». Psychopharmacology 205 (1): 119–28. 2009. doi:10.1007/s00213-009-1521-8. PMID 19337725. PMC 2821721. https://archive.org/details/sim_psychopharmacology_2009-07_205_1/page/119.
Maitre, M.; Ratomponirina, C.; Gobaille, S.; Hodé, Y.; Hechler, V. (Apr 1994). «Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics». European Journal of Pharmacology 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
Blomme, Audrey; Conraux, Laurence; Poirier, Philippe; Olivier, Anne; Koenig, Jean-Jacques; Sevrin, Mireille; Durant, François; George, Pascal (2000), «Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties», Molecular Modeling and Prediction of Bioactivity (Springer US): 404–405, doi:10.1007/978-1-4615-4141-7_97, ISBN 9781461368571

drugs.com

«Amisulpride (Barhemsys) Use During Pregnancy». Drugs.com. 2 Σεπτεμβρίου 2020. Ανακτήθηκε στις 24 Σεπτεμβρίου 2020.

fda.gov

accessdata.fda.gov

«Barhemsys (amisulpride) injection, for intravenous use» (PDF). U.S. Food and Drug Administration (FDA). Φεβρουαρίου 2020. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.

lbpharma.us

«Pipeline». LB Pharmaceuticals. Αρχειοθετήθηκε από το πρωτότυπο στις 10 Ιουλίου 2019. Ανακτήθηκε στις 29 Αυγούστου 2019.
«About Us». LB Pharmaceuticals. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.
«Data presented at 2017 ECNP meeting (European Neuropsychopharmacology, 2017, 27 (S4), S922-S923)». LB Pharmaceuticals. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.
«Building a translational bridge from animals to man for clinical candidate LB-102, a next-generation benzamide antipsychotic (P.101)» (PDF). LB Pharmaceuticals. Ανακτήθηκε στις 29 Αυγούστου 2019.

medicines.org.uk

«Amisulpride 100 mg Tablets - Summary of Product Characteristics (SmPC)». (emc). 5 Ιουλίου 2019. Αρχειοθετήθηκε από το πρωτότυπο στις 26 Φεβρουαρίου 2020. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.

medicinescomplete.com

Brayfield, A, επιμ. (Ιουνίου 2017). «Amisulpride: Martindale: The Complete Drug Reference». MedicineComplete. Pharmaceutical Press. Ανακτήθηκε στις 5 Αυγούστου 2017.

nih.gov

ncbi.nlm.nih.gov

Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G. (2002). «A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers». Human Psychopharmacology 17 (1): 1–13. doi:10.1002/hup.320. PMID 12404702. https://archive.org/details/sim_human-psychopharmacology_2002-01_17_1/page/n6.
Caccia, S (May 2000). «Biotransformation of Post-Clozapine Antipsychotics Pharmacological Implications». Clinical Pharmacokinetics 38 (5): 393–414. doi:10.2165/00003088-200038050-00002. PMID 10843459.
«The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia». Molecular Psychiatry 7 (3): 247–53. 2002. doi:10.1038/sj.mp.4001040. PMID 11920152.
Leucht, S; Cipriani, A; Spineli, L; Mavridis, D; Orey, D; Richter, F; Samara, M; Barbui, C και άλλοι. (September 2013). «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
«Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7». ACS Omega 4 (9): 14151–4. August 2019. doi:10.1021/acsomega.9b02144. ISSN 2470-1343. PMID 31497735.
Komossa, K; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI; Kissling, W; Leucht, S (January 2010). «Amisulpride versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (1): CD006624. doi:10.1002/14651858.CD006624.pub2. PMID 20091599.
Leucht, S; Corves, C; Arbter, D; Engel, RR; Li, C; Davis, JM (January 2009). «Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis». Lancet 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842.
Solanki, RK; Sing, P; Munshi, D (Oct–Dec 2009). «Current perspectives in the treatment of resistant schizophrenia». Indian Journal of Psychiatry 51 (4): 254–60. doi:10.4103/0019-5545.58289. PMID 20048449.
Mouaffak, F; Tranulis, C; Gourevitch, R; Poirier, MF; Douki, S; Olié, JP; Lôo, H; Gourion, D (2006). «Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia». Clinical Neuropharmacology 29 (1): 28–33. doi:10.1097/00002826-200601000-00009. PMID 16518132.
Nuss, P.; Hummer, M.; Tessier, C. (2007). «The use of amisulpride in the treatment of acute psychosis». Therapeutics and Clinical Risk Management 3 (1): 3–11. doi:10.2147/tcrm.2007.3.1.3. PMID 18360610.
McKeage, K; Plosker, GL (2004). «Amisulpride: a review of its use in the management of schizophrenia». CNS Drugs 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. ISSN 1172-7047. PMID 15521794.
Natesan, S; Reckless, GE; Barlow, KB; Nobrega, JN; Kapur, S (October 2008). «Amisulpride the 'atypical' atypical antipsychotic — Comparison to haloperidol, risperidone and clozapine». Schizophrenia Research 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID 18710798.
«Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica 114 (1): 3–13. July 2006. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
Isbister, GK; Balit, CR; Macleod, D; Duffull, SB (August 2010). «Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes». Journal of Clinical Psychopharmacology 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID 20531221. https://archive.org/details/sim_journal-of-clinical-psychopharmacology_2010-08_30_4/page/391.
Joy, JP; Coulter, CV; Duffull, SB; Isbister, GK (August 2011). «Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses». Clinical Pharmacology & Therapeutics 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID 21716272. https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_2011-08_90_2/page/243.
Levine, M; Ruha, AM (July 2012). «Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management». CNS Drugs 26 (7): 601–611. doi:10.2165/11631640-000000000-00000. PMID 22668123.
«Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo». Psychopharmacology 205 (1): 119–28. 2009. doi:10.1007/s00213-009-1521-8. PMID 19337725. PMC 2821721. https://archive.org/details/sim_psychopharmacology_2009-07_205_1/page/119.
Maitre, M.; Ratomponirina, C.; Gobaille, S.; Hodé, Y.; Hechler, V. (Apr 1994). «Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics». European Journal of Pharmacology 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.

pubmedcentral.nih.gov

«Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7». ACS Omega 4 (9): 14151–4. August 2019. doi:10.1021/acsomega.9b02144. ISSN 2470-1343. PMID 31497735.
Komossa, K; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI; Kissling, W; Leucht, S (January 2010). «Amisulpride versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (1): CD006624. doi:10.1002/14651858.CD006624.pub2. PMID 20091599.
Solanki, RK; Sing, P; Munshi, D (Oct–Dec 2009). «Current perspectives in the treatment of resistant schizophrenia». Indian Journal of Psychiatry 51 (4): 254–60. doi:10.4103/0019-5545.58289. PMID 20048449.
Nuss, P.; Hummer, M.; Tessier, C. (2007). «The use of amisulpride in the treatment of acute psychosis». Therapeutics and Clinical Risk Management 3 (1): 3–11. doi:10.2147/tcrm.2007.3.1.3. PMID 18360610.
«Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo». Psychopharmacology 205 (1): 119–28. 2009. doi:10.1007/s00213-009-1521-8. PMID 19337725. PMC 2821721. https://archive.org/details/sim_psychopharmacology_2009-07_205_1/page/119.

tga.gov.au

ebs.tga.gov.au

«Australian Product Information – Solian (Amisulpride) Tablets And Solution». TGA eBS. Ανακτήθηκε στις 10 Μαΐου 2020.
«Solian tablets and solution product information» (PDF). TGA eBusiness Services. Sanofi-Aventis Australia Pty Ltd. 27 Σεπτεμβρίου 2019. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.

web.archive.org

«Amisulpride 100 mg Tablets - Summary of Product Characteristics (SmPC)». (emc). 5 Ιουλίου 2019. Αρχειοθετήθηκε από το πρωτότυπο στις 26 Φεβρουαρίου 2020. Ανακτήθηκε στις 26 Φεβρουαρίου 2020.
«Pipeline». LB Pharmaceuticals. Αρχειοθετήθηκε από το πρωτότυπο στις 10 Ιουλίου 2019. Ανακτήθηκε στις 29 Αυγούστου 2019.

worldcat.org

«Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7». ACS Omega 4 (9): 14151–4. August 2019. doi:10.1021/acsomega.9b02144. ISSN 2470-1343. PMID 31497735.
McKeage, K; Plosker, GL (2004). «Amisulpride: a review of its use in the management of schizophrenia». CNS Drugs 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. ISSN 1172-7047. PMID 15521794.